Página 1 desde 20 resultados
FIELD OF THE INVENTION
The present invention relates to novel small molecule antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment
BACKGROUND OF THE INVENTION
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP-receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP
BACKGROUND OF THE INVENTION
The disclosure generally relates to the compound (R)--N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)piperaz- in-1-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-- carboxamide (Compound I or the compound of formula I), including
TECHNICAL FIELD
The present invention relates generally to a method of modulating substance P by compounds containing calcium sulfate, particularly syngenite, gorgeyite and gypsum, and more specifically, to the synthesis of such compounds as well as their use to treat a variety of conditions
FIELD OF THE DISCLOSURE
The present disclosure relates to nutritional supplements. Specifically, the present disclosure relates to nutritional supplements used to treat and/or prevent inflammation and disease states and conditions resulting from inflammation.
BACKGROUND
The human diet has been known
BACKGROUND OF THE INVENTION
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP-receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP
BACKGROUND OF THE INVENTION
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP-receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP
BACKGROUND OF THE INVENTION
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP-receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP
BACKGROUND OF THE INVENTION
The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which are CGRP-receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP
BACKGROUND OF THE INVENTION
Calcitonin gene-related peptide (CGRP) is a naturally occurring 37-amino-acid peptide first identified in 1982 (Amara, S. G. et al, Science 1982, 298, 240-244). Two forms of the peptide are expressed (.alpha.CGRP and .beta.CGRP) which differ by one and three amino acids
BACKGROUND OF THE INVENTION
Calcitonin gene-related peptide (CGRP) is a naturally occurring 37-amino-acid peptide first identified in 1982 (Amara, S. G. et al, Science 1982, 298, 240-244). Two forms of the peptide are expressed (.alpha.CGRP and .beta.CGRP) which differ by one and three amino acids
BACKGROUND OF THE INVENTION
Calcitonin gene-related peptide (CGRP) is a naturally occurring 37-amino-acid peptide first identified in 1982 (Amara, S. G. et al, Science 1982, 298, 240-244). Two forms of the peptide are expressed (.alpha.CGRP and .beta.CGRP) which differ by one and three amino acids
BACKGROUND OF THE INVENTION
Calcitonin gene-related peptide (CGRP) is a naturally occurring 37-amino-acid peptide first identified in 1982 (Amara, S. G. et al, Science 1982, 298, 240-244). Two forms of the peptide are expressed (.alpha.CGRP and .beta.CGRP) which differ by one and three amino acids
BACKGROUND OF THE INVENTION
Calcitonin gene-related peptide (CGRP) is a naturally occurring 37-amino-acid peptide first identified in 1982 (Amara, S. G. et al, Science 1982, 298, 240-244). Two forms of the peptide are expressed (.alpha.CGRP and .beta.CGRP) which differ by one and three amino acids
FIELD OF THE INVENTION
The present invention relates to novel small molecule antagonists of calcitonin gene-related peptide receptors ("CGRP-receptor"), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment